We’re tackling cancer head-on

At Mirati, we are relentlessly focused on developing best-in-class targeted therapies to meaningfully impact the lives of patients with cancer

Video: Learn more about our mission and commitment to patients

Learn more about KRAS mutations

 

At Mirati, we convert possibility into reality by developing best-in-class targeted therapies to improve the lives of patients.

Our Programs

KRAS
KRAS

Our scientists are rigorously advancing research and development programs targeting the KRASG12C and KRASG12D mutations.

Sitravatinib
Sitravatinib

We are exploring new ways of targeting the protective nest of cells, tissues and blood vessels that make up the tumor microenvironment.

MRTX1719
MRTX1719

MRTX1719 is an investigational, internally discovered synthetic lethal PRMT5 inhibitor for the treatment of methylthioadenosine phosphoylase (MTAP)-deleted cancers.

Mirati is developing a pipeline of novel therapeutics.

Become part of something bigger.